{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:13:41Z","timestamp":1790813621813,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd002202","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T00:00:00Z","timestamp":1492646400000}}],"reference-count":199,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002202.pub2","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T08:35:16Z","timestamp":1492677316000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Hydroxyurea (hydroxycarbamide) for sickle cell disease"],"prefix":"10.1002","volume":"2017","author":[{"given":"Sarah J","family":"Nevitt","sequence":"first","affiliation":[{"name":"University of Liverpool; Department of Biostatistics; Block F, Waterhouse Building 1-5 Brownlow Hill Liverpool UK L69 3GL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley P","family":"Jones","sequence":"additional","affiliation":[{"name":"University of Liverpool; Department of Biostatistics; Block F, Waterhouse Building 1-5 Brownlow Hill Liverpool UK L69 3GL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Howard","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas' Hospitals NHS Foundation Trust; Department of Haematology; Great Maze Pond London UK SE1 9RT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,20]]},"reference":[{"issue":"11","key":"10.1002\/14651858.CD002202.pub2-BIB0001|cit1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.952.952","article-title":"TCD in infants: A report from the BABY HUG trial","volume":"106","author":"Adams","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0002|cit2","unstructured":"Adams RJ Luden J Miller S Wang W Rees R Li D TCD in infants: a report from the Baby Hug study 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio 2005 105"},{"issue":"4","key":"10.1002\/14651858.CD002202.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/pbc.24100","article-title":"Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia","volume":"59","author":"Alvarez","year":"2012","journal-title":"Pediatric Blood & Cancer"},{"issue":"2","key":"10.1002\/14651858.CD002202.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1542\/peds.2012-0283","article-title":"Developmental function in toddlers with sickle cell anemia","volume":"131","author":"Armstrong","year":"2013","journal-title":"Pediatrics"},{"issue":"11","key":"10.1002\/14651858.CD002202.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.V112.11.713.713","article-title":"Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial","volume":"112","author":"Armstrong","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0006|cit6","unstructured":"Armstrong FD Rees RC Li D Bonner M Elkin D Strouse JJ Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug) 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio 2005 137"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0007|cit7","unstructured":"Casella JF Wang WC Rogers ZR Iyer RV Rana S Driscoll MC Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function Pediatric Academic Societies Annual Meeting 2005 1111"},{"issue":"3","key":"10.1002\/14651858.CD002202.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.clinbiochem.2012.10.032","article-title":"Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial","volume":"46","author":"Kalpatthi","year":"2013","journal-title":"Clinical Biochemistry"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0009|cit9","unstructured":"Lebensburger JD Miller ST Howard TH Casella JF Brown RC Lu M Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando 2010"},{"issue":"4","key":"10.1002\/14651858.CD002202.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/pbc.24037","article-title":"Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study","volume":"59","author":"Lebensburger","year":"2012","journal-title":"Pediatric Blood & Cancer"},{"issue":"4","key":"10.1002\/14651858.CD002202.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1542\/peds.2014-0571","article-title":"Immunologic effects of hydroxyurea in sickle cell anemia","volume":"134","author":"Lederman","year":"2014","journal-title":"Pediatrics"},{"issue":"21","key":"10.1002\/14651858.CD002202.pub2-BIB0012|cit12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.243.243","article-title":"Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400)","volume":"120","author":"Lederman","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD002202.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2214\/AJR.10.4664","article-title":"Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial","volume":"196","author":"McCarville","year":"2011","journal-title":"AJR American Journal of Roentgenology"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0014|cit14","unstructured":"McCarville MB Rees RC Rogers ZR Kalpatthi R Miller ST Wang WC Adbominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20 2009"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0015|cit15","unstructured":"McGann PT Flanagan JM Howard TA Dertinger SD He J Kulharya AS Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California 2011"},{"issue":"2","key":"10.1002\/14651858.CD002202.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.23365","article-title":"Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial","volume":"59","author":"McGann","year":"2012","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0017|cit17","unstructured":"Miller ST Barredo J Brown C Bonds DR Casella JF Li D Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA 2006"},{"issue":"1","key":"10.1002\/14651858.CD002202.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/pbc.23244","article-title":"Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia","volume":"59","author":"Miller","year":"2012","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Miller ST Wang WC Iyer R Rana S Lane P Ware RE Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG) Pediatric Blood & Cancer 2010 265 8","DOI":"10.1002\/pbc.22189"},{"issue":"11","key":"10.1002\/14651858.CD002202.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V112.11.1413.1413","article-title":"Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial","volume":"112","author":"Miller","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD002202.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1182\/blood.V112.11.4791.4791","article-title":"Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial","volume":"112","author":"Miller","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Pavlakis SG Rees RC Huang X Brown RC Casella JF Iyer RV Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial Pediatric Blood & Cancer 2010 256 9","DOI":"10.1002\/pbc.22282"},{"issue":"3","key":"10.1002\/14651858.CD002202.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"465-472. Supple","DOI":"10.1542\/peds.2014-0917","article-title":"Hydroxyurea and growth in young children with sickle cell disease","volume":"134","author":"Rana","year":"2014","journal-title":"Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD002202.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1542\/peds.2014-0917","article-title":"Hydroxyurea and growth in young children with sickle cell disease","volume":"134","author":"Rana","year":"2014","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0025|cit25","unstructured":"Rogers ZR Capparelli EV Thompson B Ware RE Wang WC Iyer RV Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA 2006 157"},{"issue":"11","key":"10.1002\/14651858.CD002202.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1182\/blood.V112.11.1416.1416","article-title":"Spleen function in infants with sickle cell anemia : baseline data from the BABY HUG trial","volume":"112","author":"Rogers","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0027|cit27","unstructured":"Rogers ZR Rees RC Files B Iyer RV Shulkin BL Shalaby-Rana E Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20 2009"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0028|cit28","unstructured":"Rogers ZR Rees RR Wang WC Li D Iyer RV Rana S Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio 2005 106"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0029|cit29","doi-asserted-by":"crossref","unstructured":"Rogers ZR Thompson B Ware RE Wang WC Iyer RV Miller ST Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial Blood 2005","DOI":"10.1182\/blood.V106.11.3184.3184"},{"issue":"7","key":"10.1002\/14651858.CD002202.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ajh.23457","article-title":"Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes","volume":"88","author":"Sheehan","year":"2013","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Thompson BW Miller ST Rogers ZR Rees RC Ware RE Waclawiw MA The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design Pediatric Blood & Cancer 2010 250 5","DOI":"10.1002\/pbc.22269"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0032|cit32","unstructured":"Thompson BW Wang WC Miller ST Rogers ZR Ware RE Thornburg CD The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA) 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego 2011"},{"issue":"22","key":"10.1002\/14651858.CD002202.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"4304-10; quiz 4","DOI":"10.1182\/blood-2012-03-419879","article-title":"Impact of hydroxyurea on clinical events in the BABY HUG trial","volume":"120","author":"Thornburg","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0034|cit34","doi-asserted-by":"crossref","unstructured":"Thornburg CD Rogers ZR Jeng MR Rana SR Iyer RV Faughnan L Adherence to study medication and visits: data from the BABY HUG trial Pediatric Blood & Cancer 2010 260 4","DOI":"10.1002\/pbc.22324"},{"issue":"11","key":"10.1002\/14651858.CD002202.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood.V112.11.1275.1275","article-title":"Study drug and visit adherence: data from the Baby HUG trial","volume":"112","author":"Thornburg","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0036|cit36","first-page":"E20","article-title":"Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: Analysis F from the BABY HUG trial","volume":"7","author":"Wang","year":"2012","journal-title":"American Journal of Hematology"},{"issue":"11","key":"10.1002\/14651858.CD002202.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1182\/blood.V112.11.1436.1436","article-title":"Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD002202.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1542\/peds.2013-0333","article-title":"Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia","volume":"132","author":"Wang","year":"2013","journal-title":"Pediatrics"},{"issue":"9778","key":"10.1002\/14651858.CD002202.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0040|cit40","unstructured":"Wang WC Yeku SO Luo Z Boulet SL Miller ST Fish B Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego 2011"},{"issue":"11","key":"10.1002\/14651858.CD002202.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1182\/blood.V112.11.1414.1414","article-title":"Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial","volume":"112","author":"Ware","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0042|cit42","doi-asserted-by":"crossref","unstructured":"Ware RE Rees RC Sarnaik SA Iyer RV Alvarez OA Casella JF Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial Journal of Pediatrics 2010 66 70","DOI":"10.1016\/j.jpeds.2009.06.060"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0043|cit43","unstructured":"Wynn L Debenham E Faughnan L Martin B Kelly T Reed C Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA 2007 245"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Wynn L Miller S Faughnan L Luo Z Debenham E Adix L Recruitment of infants with sickle cell anemia to a Phase III trial: data from the BABY HUG study Contemporary Clinical Trials 2010 558 63","DOI":"10.1016\/j.cct.2010.08.007"},{"issue":"11","key":"10.1002\/14651858.CD002202.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/blood.V112.11.1429.1429","article-title":"Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study","volume":"112","author":"Wynn","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD002202.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood.V88.6.1960.bloodjournal8861960","article-title":"Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial","volume":"88","author":"Ferster","year":"1996","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD002202.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2141.2010.08523.x","article-title":"The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial","volume":"152","author":"Wang","year":"2011","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0048|cit48","doi-asserted-by":"crossref","unstructured":"Wang WC Snyder C Brugnara C Telen MJ Steinberg MH Wynn LW Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the \"CHAMPS\" trial Blood 2009","DOI":"10.1182\/blood.V114.22.819.819"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0049|cit49","unstructured":"Jain D Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study 4th Annual Sickle Cell Disease Research and Educational Symposium & Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida 2010"},{"issue":"4","key":"10.1002\/14651858.CD002202.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/03630269.2012.697948","article-title":"Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease","volume":"36","author":"Jain","year":"2012","journal-title":"Hemoglobin"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Armstrong FD Steinberg MH Ballas SK Ataga KI Waclawiw MA Kutlar A Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea Blood 2009","DOI":"10.1182\/blood.V114.22.1543.1543"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD002202.pub2-BIB0052|cit52","first-page":"642a","article-title":"Narcotic analgesia use among adult patients with sickle cell anemia","volume":"86","author":"Ballas","year":"1995","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0053|cit53","unstructured":"Ballas SK Barton F Castro O Koshy M Bellevue R Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar 1996 63"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1477-7525-4-59","article-title":"Hydroxyurea and sickle cell anemia: effect on quality of life","volume":"4","author":"Ballas","year":"2006","journal-title":"Health and Quality of Life Outcomes"},{"issue":"8","key":"10.1002\/14651858.CD002202.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ajh.21750","article-title":"Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: Effect of sex,age, and geographical location","volume":"85","author":"Ballas","year":"2010","journal-title":"American Journal of Hematology"},{"issue":"6","key":"10.1002\/14651858.CD002202.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jpainsymman.2010.03.020","article-title":"Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home","volume":"40","author":"Ballas","year":"2010","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0058|cit57","doi-asserted-by":"crossref","unstructured":"Ballas SK Bauserman RL McCarthy WF Waclawiw MA The impact of hydroxyurea on career and employment of patients with sickle cell anemia JAMA 2010 993 9","DOI":"10.1016\/S0027-9684(15)30725-2"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0057|cit58","doi-asserted-by":"crossref","unstructured":"Ballas SK Bauserman RL McCarthy WF Waclawiw MA Barton BA Impact of hydroxyurea on employment among patients with sickle cell anemia Blood 2009","DOI":"10.1182\/blood.V114.22.2485.2485"},{"issue":"2","key":"10.1002\/14651858.CD002202.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2141.1999.01339.x","article-title":"Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea","volume":"105","author":"Ballas","year":"1999","journal-title":"British Journal of Haematology"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD002202.pub2-BIB0060|cit60","first-page":"140a","article-title":"In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea","volume":"86","author":"Ballas","year":"1995","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Ballas SK McCarthy WF Bauseman RI Castro OL Swerdlow PS Smith W Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH) Blood 2009","DOI":"10.1182\/blood.V114.22.2577.2577"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0062|cit62","doi-asserted-by":"crossref","unstructured":"Ballas SK McCarthy WF Bauserman RL Castro OL Waclawiw MA Barton BA Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia Blood 2009","DOI":"10.1182\/blood.V114.22.2582.2582"},{"issue":"22","key":"10.1002\/14651858.CD002202.pub2-BIB0063|cit63","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1513.1513","article-title":"Definition of the responder to hydroxyurea therapy: revisited","volume":"114","author":"Ballas","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0064|cit64","unstructured":"Ballas SK McCarthy WF Guo N Brugnara C Kling G Bauserman R Early detection of responders to hydroxyurea therapy 4th Annual Sickle Cell Disease Research and Educational Symposium & Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida 2010"},{"issue":"10","key":"10.1002\/14651858.CD002202.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0027-9684(15)31072-5","article-title":"Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia","volume":"101","author":"Ballas","year":"2009","journal-title":"Journal of the National Medical Association"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD002202.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"67S","DOI":"10.1016\/0197-2456(96)84580-6","article-title":"Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in Sickle Cell Anemia (MSH). The MSH Investigators","volume":"17","author":"Barton","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0067|cit67","first-page":"209","article-title":"Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study","volume":"2","author":"Brandon","year":"2004","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0071|cit68","first-page":"326","article-title":"Effects of hydroxyurea therapy in patients with sickle cell anemia","volume":"26","author":"Charache","year":"1996","journal-title":"Australian and New Zealand Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002202.pub2-BIB0072|cit69","first-page":"62","article-title":"Experimental therapy of sickle cell disease. Use of hydroxyurea","volume":"16","author":"Charache","year":"1994","journal-title":"American Journal of Pediatric Hematology\/Oncology"},{"issue":"3 Suppl 3","key":"10.1002\/14651858.CD002202.pub2-BIB0073|cit70","first-page":"15","article-title":"Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults","volume":"34","author":"Charache","year":"1997","journal-title":"Seminars in Hematology"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD002202.pub2-BIB0074|cit71","first-page":"356a","article-title":"Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial","volume":"82","author":"Charache","year":"1993","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD002202.pub2-BIB0068|cit72","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00005792-199611000-00002","article-title":"Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive \"switching\" agent","volume":"75","author":"Charache","year":"1996","journal-title":"Medicine"},{"issue":"20","key":"10.1002\/14651858.CD002202.pub2-BIB0069|cit73","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002202.pub2-BIB0070|cit74","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0197-2456(95)00098-4","article-title":"Design of the multicenter study of hydroxyurea in sickle cell anemia","volume":"16","author":"Charache","year":"1995","journal-title":"Controlled Clinical Trials"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD002202.pub2-BIB0075|cit75","first-page":"141a","article-title":"Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia","volume":"86","author":"Hackney","year":"1995","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD002202.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1042\/cs0920481","article-title":"Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia","volume":"92","author":"Hackney","year":"1997","journal-title":"Clinical Science"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002202.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"92S","DOI":"10.1016\/0197-2456(96)84623-X","article-title":"Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH)","volume":"17","author":"Handy","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0078|cit78","unstructured":"Heizer WD Hackney AC Busby M Gulledge T Jones S Strayhorn G The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): An ancillary study to the multicentre study of hydroxyurea (MSH) National Sickle Cell Disease Program 18th Annual Meeting; 1993 May 1993 117a"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0079|cit79","unstructured":"Kutlar A Barton F Terrin M Steinberg MH Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: The MSH at 7-8 years follow-up National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr 2001"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0080|cit80","article-title":"Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial","volume":"11","author":"McCarthy","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD002202.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0197-2456(97)00014-7","article-title":"An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH)","volume":"18","author":"McMahon","year":"1997","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0082|cit82","unstructured":"Moore RD Charache S Terrin M Barton FB Ballas SK Cost-effectiveness of hydroxyurea in sickle cell anemia National Sickle Cell Disease Program 23rd Meeting; 1999 Mar 1999 210"},{"issue":"1","key":"10.1002\/14651858.CD002202.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<26::AID-AJH5>3.0.CO;2-F","article-title":"Cost-effectiveness of hydroxyurea in sickle cell anemia","volume":"64","author":"Moore","year":"2000","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0084|cit84","unstructured":"Orringer EP Jones S Strayhorn D Hoffman E Parker J Greenberg C The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS) National Sickle Cell Disease Program 21st Meeting; 1996 Mar 1996 131"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD002202.pub2-BIB0085|cit85","first-page":"496a","article-title":"The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia","volume":"88","author":"Orringer","year":"1996","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD002202.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1526-4637.2011.01096.x","article-title":"The association between hydroxyurea treatment and pain intensity, analgesic use,\u00a0 and utilization in ambulatory sickle cell anemia patients","volume":"12","author":"Smith","year":"2011","journal-title":"Pain Medicine"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0087|cit87","unstructured":"Smith WR Bauseman RL McCarthy WF Barton BA Ballas SK Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20 2009"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002202.pub2-BIB0096|cit88","first-page":"8","article-title":"Determinants of fetal hemoglobin response to hydroxyurea","volume":"3","author":"Steinberg","year":"1997","journal-title":"Seminars in Hematology"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0097|cit89","unstructured":"Steinberg MH Mortality at 3-5 years: The multicenter study of hydroxyurea in sickle cell anemia (MSH) National Sickle Cell Disease Program Annual Meeting; 1997 Sep 1997 68"},{"issue":"10 Suppl 1 Pt 1","key":"10.1002\/14651858.CD002202.pub2-BIB0088|cit90","first-page":"444a","article-title":"Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH)","volume":"90","author":"Steinberg","year":"1997","journal-title":"Blood"},{"issue":"10 Suppl 1 Pt 1","key":"10.1002\/14651858.CD002202.pub2-BIB0089|cit91","first-page":"644a","article-title":"Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years","volume":"94","author":"Steinberg","year":"1999","journal-title":"Blood"},{"issue":"13","key":"10.1002\/14651858.CD002202.pub2-BIB0090|cit92","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD002202.pub2-BIB0091|cit93","first-page":"485a","article-title":"Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia","volume":"96","author":"Steinberg","year":"2000","journal-title":"Blood"},{"issue":"10 Suppl 1 Pt 1","key":"10.1002\/14651858.CD002202.pub2-BIB0092|cit94","first-page":"496a","article-title":"The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years","volume":"92","author":"Steinberg","year":"1998","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD002202.pub2-BIB0093|cit95","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood.V89.3.1078","article-title":"Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea","volume":"89","author":"Steinberg","year":"1997","journal-title":"Blood"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD002202.pub2-BIB0094|cit96","first-page":"418a","article-title":"Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU)","volume":"86","author":"Steinberg","year":"1995","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0095|cit97","doi-asserted-by":"crossref","unstructured":"Steinberg MH McCarthy WF Castro O Ballas SK Armstrong FD Smith W The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up American Journal of Hematolology 2010 403 8","DOI":"10.1002\/ajh.21699"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0098|cit98","unstructured":"Terrin ML Barton FB Bonds D Ballas SK Swerdlow P Pegelow CH Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar 1999 161"},{"issue":"12","key":"10.1002\/14651858.CD002202.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/ajh.24198","article-title":"Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial","volume":"90","author":"Hankins","year":"2015","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0100|cit100","unstructured":"NCT01531387 Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE) http:\/\/clinicaltrials.gov\/show\/NCT01531387"},{"issue":"11","key":"10.1002\/14651858.CD002202.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/ajh.23547","article-title":"Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial","volume":"88","author":"Alvarez","year":"2013","journal-title":"American Journal of Hematology"},{"issue":"2","key":"10.1002\/14651858.CD002202.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.13280","article-title":"Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload","volume":"169","author":"Aygun","year":"2015","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0103|cit103","unstructured":"Aygun B Mortier NA Kesler K Schultz WH Alvarez OA Rogers ZR Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California 2011"},{"issue":"2","key":"10.1002\/14651858.CD002202.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ajh.22228","article-title":"Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention","volume":"87","author":"Kwiatkowski","year":"2012","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0105|cit105","unstructured":"NCT00122980 Stroke with transfusions changing to hydroxyurea clinicaltrials.gov\/show\/NCT00122980"},{"issue":"21","key":"10.1002\/14651858.CD002202.pub2-BIB0106|cit106","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.241.241","article-title":"Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia","volume":"120","author":"Sheehan","year":"2012","journal-title":"Blood"},{"issue":"17","key":"10.1002\/14651858.CD002202.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1182\/blood-2011-11-392340","article-title":"Stroke With Transfusions Changing to Hydroxyurea (SWiTCH)","volume":"119","author":"Ware","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0108|cit108","doi-asserted-by":"crossref","unstructured":"Ware RE Helms RW Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia 52nd ASH Meeting and Exposisiton; 2010 Dec 4-7; Orlando, Florida 2010","DOI":"10.1182\/blood.V116.21.844.844"},{"issue":"11","key":"10.1002\/14651858.CD002202.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"Abst 1213","DOI":"10.1182\/blood.V108.11.1213.1213","article-title":"Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke","volume":"108","author":"Ware","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD002202.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/pbc.23145","article-title":"Stroke with transfusions changing to hydroxyurea (SWiTCH): A phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload","volume":"57","author":"Ware","year":"2011","journal-title":"Pediatric Blood & Cancer"},{"issue":"4","key":"10.1002\/14651858.CD002202.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/ajh.23105","article-title":"Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities","volume":"87","author":"Aygun","year":"2012","journal-title":"American Journal of Hematology"},{"issue":"21","key":"10.1002\/14651858.CD002202.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1182\/blood.V124.21.4052.4052","article-title":"Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia","volume":"124","author":"Helton","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1002\/14651858.CD002202.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/blood.V124.21.87.87","article-title":"Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial","volume":"124","author":"Imran","year":"2014","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(15)01041-7","article-title":"Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial","volume":"387","author":"Ware","year":"2016","journal-title":"Lancet"},{"issue":"21","key":"10.1002\/14651858.CD002202.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1182\/blood.V122.21.2238.2238","article-title":"Extrahepatic iron deposition in chronically transfused children with sickle cell anemia- baseline findings from the Twitch trial","volume":"122","author":"Wood","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD002202.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bjh.13791","article-title":"Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial","volume":"172","author":"Wood","year":"2016","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1002\/14651858.CD002202.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24089","article-title":"Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial","volume":"90","author":"Wood","year":"2015","journal-title":"American Journal of Hematology"},{"issue":"9","key":"10.1002\/14651858.CD002202.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24089","article-title":"Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial","volume":"90","author":"Wood","year":"2015","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0119|cit119","doi-asserted-by":"crossref","unstructured":"Al-Nood HA Al-Khawlani MM Al-Akwa A Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients Hemoglobin 2011 13 21","DOI":"10.3109\/03630269.2011.551748"},{"issue":"11","key":"10.1002\/14651858.CD002202.pub2-BIB0120|cit120","first-page":"Abst 3194","article-title":"A phase 1 pharmacokinetics (PK) study of hydroxyurea (HU) 1,000 mg coated breakable tablets and 500mg capsules in pediatric and adult patients with sickle cell disease","volume":"106","author":"Montalembert","year":"2005","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD002202.pub2-BIB0121|cit121","first-page":"1685","article-title":"Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease","volume":"91","author":"Montalembert","year":"2006","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0122|cit122","article-title":"A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in children with sickle cell anemia","volume":"60 Suppl","author":"George","year":"2013","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0123|cit123","unstructured":"NCT00004492. Phase I\/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia https:\/\/clinicaltrials.gov\/show\/NCT00004492"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0124|cit124","unstructured":"NCT01848925 A Phase I Open-label, Randomized, Safety and Efficacy Study of SANGUINATE\u2122 at Two Doses Levels Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients clinicaltrials.gov\/show\/NCT01848925"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0125|cit125","unstructured":"NCT01960413. Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia https:\/\/clinicaltrials.gov\/show\/NCT01960413"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0126|cit126","unstructured":"NCT02149537. Risk Stratification for Clinical Severity of Sickle Cell Disease in Nigeria and Assessment of Efficacy and Safety During Treatment With Hydroxyurea https:\/\/clinicaltrials.gov\/show\/NCT02149537"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD002202.pub2-BIB0127|cit127","first-page":"34, Abstract no","article-title":"Hydroxyurea ameliorates importantly the clinical course of sickle cell disease reducing the frequency of painful crises","volume":"1","author":"Pushi","year":"2000","journal-title":"Hematology Journal"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0128|cit128","first-page":"298","article-title":"Hydroxyurea treatment of sickle cell diseases causes megaloblastic transformation of the bone marrow that is responsible for the increase of the mean corpuscular volume","volume":"Suppl 1","author":"Silva-Pinto","year":"2007","journal-title":"Haematologica"},{"issue":"9","key":"10.1002\/14651858.CD002202.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00277-014-2066-4","article-title":"Hydroxycarbamide modulates components involved in the regulation of adenosine levels in blood cells from sickle-cell anemia patients","volume":"93","author":"Silva-Pinto","year":"2014","journal-title":"Annals of Hematology"},{"issue":"21","key":"10.1002\/14651858.CD002202.pub2-BIB0130|cit130","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.1082.1082","article-title":"A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD0: 2-year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy","volume":"118","author":"Vichinsky","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD002202.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/ajh.23569","article-title":"Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea","volume":"88","author":"Vichinsky","year":"2013","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0132|cit132","unstructured":"Voskaridou E Terpos E Margeli A Hantzi E Meletis J Papassotiriou I Renal dysfunction and osteodystrophy in patients with sickle cell thalassaemia under long-term treatment with hydroxyurea 10th Congress of the European Hematology Association; 2005 June 2-5; Stockholm International Fairs, Sweden 2005"},{"issue":"2","key":"10.1002\/14651858.CD002202.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.2196\/resprot.5599","article-title":"Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial","volume":"5","author":"Anyanwu","year":"2016","journal-title":"JMIR research protocols"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0134|cit134","unstructured":"NCT02560935 Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II (SPRING) clinicaltrials.gov\/show\/NCT02560935"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0135|cit135","unstructured":"NCT02675790 Low Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa (SPRINT) clinicaltrials.gov\/ct2\/show\/NCT02675790"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0136|cit136","unstructured":"NCT01389024 Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease (HUPrevent) clinicaltrials.gov\/ct2\/show\/NCT01389024"},{"issue":"7","key":"10.1002\/14651858.CD002202.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"E131","DOI":"10.1002\/ajh.24010","article-title":"Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia","volume":"90","author":"Aumont","year":"2015","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0138|cit138","unstructured":"Ballas SK Barton F Castro O Koshy M Bellevue R Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar 1996 63"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1477-7525-4-59","article-title":"Hydroxyurea and sickle cell anemia: effect on quality of life","volume":"4","author":"Ballas","year":"2006","journal-title":"Health and Quality of Life Outcomes"},{"issue":"10","key":"10.1002\/14651858.CD002202.pub2-BIB0140|cit140","first-page":"1046","article-title":"Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia","volume":"101","author":"Ballas","year":"2009","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"67S","DOI":"10.1016\/0197-2456(96)84580-6","article-title":"Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in Sickle Cell Anemia (MSH). The MSH Investigators","volume":"17","author":"Barton","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4137\/CMO.S8810","article-title":"Development of myelodysplastic syndrome and acute myeloid leukemia 15 years after hydroxyurea use in a patient with sickle cell anemia","volume":"6","author":"Baz","year":"2012","journal-title":"Clinical Medicine Insights. Oncology"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0143|cit143","first-page":"166","article-title":"Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group","volume-title":"Polycythemia Vera and the Myeloproliferation Disorders","author":"Berk","year":"1995"},{"issue":"15","key":"10.1002\/14651858.CD002202.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood-2015-10-675231","article-title":"Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities","volume":"127","author":"Bernaudin","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD002202.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3324\/haematol.11515","article-title":"Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males","volume":"93","author":"Berthaut","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"10.1002\/14651858.CD002202.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajh.21570","article-title":"The number of people with sickle-cell disease in the United States: national and state estimates","volume":"85","author":"Brousseau","journal-title":"American journal of hematology"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/pgmj.63.742.605","article-title":"Management of sickle cell disease","volume":"63","author":"Brozovic","year":"1987","journal-title":"Postgraduate Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD002202.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/archdischild-2013-303773","article-title":"Sickle cell disease: a neglected chronic disease of increasing global health importance","volume":"100","author":"Chakravorty","year":"2015","journal-title":"Archives of Disease in Childhood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anaemia","volume":"332","author":"Charache","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0268-960X(97)90012-6","article-title":"Blood transfusion in sickle cell disease","volume":"11","author":"Davies","year":"1997","journal-title":"Blood Reviews"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/bmj.315.7109.656","article-title":"The management of patients with sickle cell disease","volume":"315","author":"Davies","year":"1997","journal-title":"British Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD002202.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analysis involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002202.pub2-BIB0153|cit153","first-page":"518a","article-title":"Acute leukemia (AL), hydroxyurea (HU), and polycythemia vera (PV): an analysis of risk from the Polycythemia Vera Study Group","volume":"84","author":"Fruchtman","year":"1994","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/adc.75.3.199","article-title":"Pain, quality of life, and coping in sickle cell disease","volume":"75","author":"Fuggle","year":"1996","journal-title":"Archives of Disease in Childhood"},{"issue":"10","key":"10.1002\/14651858.CD002202.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1182\/blood-2016-05-716910","article-title":"Survival in adults with sickle cell disease in a high income setting","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/jcp.44.6.459","article-title":"Mortality in sickle cell disease: the experience of a British centre","volume":"44","author":"Gray","year":"1991","journal-title":"Journal of Clinical Pathology"},{"issue":"1-2","key":"10.1002\/14651858.CD002202.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/pr.2013.227","article-title":"Emerging science of hydroxyurea therapy for pediatric sickle cell disease","volume":"75","author":"Green","year":"2013","journal-title":"Pediatric research"},{"issue":"6","key":"10.1002\/14651858.CD002202.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"S398","DOI":"10.1016\/j.amepre.2011.09.013","article-title":"Sickle cell disease in Africa: a neglected cause of early childhood mortality","volume":"41","author":"Grosse","journal-title":"American journal of preventive medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002202.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"92S","DOI":"10.1016\/0197-2456(96)84623-X","article-title":"Dose titration in the Multicentre Study of Hydroxyurea in Sickle Cell Anemia (MSH)","volume":"17","author":"Handy","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"28","key":"10.1002\/14651858.CD002202.pub2-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1097\/MD.0000000000000215","article-title":"From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia","volume":"93","author":"Hankins","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1002\/14651858.CD002202.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the US","volume":"38","author":"Hassell","journal-title":"American journal of preventive medicine"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0163|cit163","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org."},{"key":"10.1002\/14651858.CD002202.pub2-BIB0164|cit164","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4471-2473-3","volume-title":"Sickle Cell Disease in Clinical Practice","author":"Howard","year":"2015"},{"issue":"1","key":"10.1002\/14651858.CD002202.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1740774508100984","article-title":"Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials","volume":"6","author":"Jones","year":"2009","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality Rates and Age at Death from Sickle Cell Disease: US. 1979-2005","volume":"128","author":"Lanzkron","year":"2013","journal-title":"Public Health Reports"},{"issue":"2","key":"10.1002\/14651858.CD002202.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.24255","article-title":"Effects of hydroxyurea treatment for patients with hemoglobin SC disease","volume":"91","author":"Luchtman-Jones","year":"2016","journal-title":"American Journal of Hematology"},{"issue":"2","key":"10.1002\/14651858.CD002202.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1046\/j.1365-2141.2003.04594.x","article-title":"Causes of death in sickle cell disease: an autopsy study","volume":"123","author":"Manci\u00a0EA","year":"2003","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD002202.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2141.2011.08698.x","article-title":"Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure","volume":"154","author":"McGann","year":"2011","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1002\/14651858.CD002202.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years","volume":"90","author":"Najean","year":"1997","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0171|cit171","unstructured":"National Toxicology Program NTP-CERHR monograph on the potential human reproductive and developmental effects of hydroxyurea NTP CERHR MON 2008 vii-viii, v, ix-III1"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0172|cit172","unstructured":"NCEPOD \u2018Sickle: A sickle crisis?\u2019 A report of the national confidential enquiry into patient outcome and death. 2008 www.ncepod.org.uk.2008sc.html"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0173|cit173","unstructured":"National Insititute of Clinical Excellence (NICE) Sickle cell acute painful episode: management of an acute painful sickle cell episode in hospital http:\/\/www.nice.org.uk\/guidance\/cg143 (accessed 06 March 2017) 2012"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0174|cit174","unstructured":"Evidence Based Management of Sickle Cell Disease. Expert Panel Report. National Institute of Health. 2014 www.nhlbi.nih.gov\/sites\/www.nhlbi.nih.gov\/files\/sickle-cell-disease-report%20020816.pdf"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-88-1-1","article-title":"Natural history of sickle cell anaemia in Saudi Arabs: a study of 270 subjects","volume":"88","author":"Perrine","year":"1978","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002202.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/sj.thj.6200147","article-title":"Patterns of mortality in sickle cell disease in adults in France and England","volume":"3","author":"Perronne","year":"2002","journal-title":"Haematology Journal"},{"issue":"9861","key":"10.1002\/14651858.CD002202.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(12)61229-X","article-title":"Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates","volume":"381","author":"Piel","year":"2013","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0178|cit178","first-page":"268","article-title":"Hydroxyurea increases fetal hemoglobin production in sickle cell anemia","volume":"97","author":"Platt","year":"1984","journal-title":"Transactions of the Association of American Physicians"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease - life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1542\/peds.71.6.927","article-title":"Is there an increased risk of Haemophilus influenzae septicemia in sickle cell anaemia?","volume":"71","author":"Powars","year":"1983","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease","volume":"115","author":"Quinn","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/bmj.1.6126.1515","article-title":"Early deaths in Jamaican children with sickle cell disease","volume":"1","author":"Rogers","year":"1978","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199904013401307","article-title":"The Management of Sickle Cell Disease","volume":"340","author":"Steinberg","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"10.1002\/14651858.CD002202.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0185|cit185","doi-asserted-by":"crossref","unstructured":"Steinberg MH McCarthy WF Castro O Ballas SK Armstrong FD Smith W The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up American Journal of Hematolology 2010 403 8","DOI":"10.1002\/ajh.21699"},{"issue":"2","key":"10.1002\/14651858.CD002202.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","article-title":"Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion","volume":"91","author":"Sterkers","year":"1998","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD002202.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood-2005-10-009506","article-title":"Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results","volume":"108","author":"Lee","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD002202.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1542\/peds.2008-0441","article-title":"Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children","volume":"122","author":"Strouse","year":"2008","journal-title":"Pediatrics"},{"issue":"7","key":"10.1002\/14651858.CD002202.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3324\/haematol.10937","article-title":"Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London.","volume":"92","author":"Telfer","year":"2007","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0190|cit190","unstructured":"Terrin ML Barton FB Bonds D Ballas SK Swerdlow P Pegelow CH Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar 1999 161"},{"issue":"5","key":"10.1002\/14651858.CD002202.pub2-BIB0191|cit191","first-page":"367","article-title":"Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease","volume":"36","author":"Triadou","year":"1994","journal-title":"Nouvelle Revue Francaise d Hematologie"},{"issue":"1","key":"10.1002\/14651858.CD002202.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2141.2011.08806.x","article-title":"Mortality and causes of death in children with sickle cell disease in the Netherlands, before the introduction of neonatal screening","volume":"155","author":"Plas","year":"2011","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1056\/NEJM198512193132503","article-title":"Stimulation of F-cell production in patients with sickle cell anaemia treated with cytarabine or hydroxyurea","volume":"313","author":"Veith","year":"1985","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2009-05-221333","article-title":"The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-centre trial (LaSHS)","volume":"115","author":"Voskaridou","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD002202.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"Abst 1213","DOI":"10.1182\/blood.V108.11.1213.1213","article-title":"Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke","volume":"108","author":"Ware","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1182\/blood-2009-04-146852","article-title":"How I use hydroxyurea to treat young patients with sickle cell anemia","volume":"115","author":"Ware","year":"2010","journal-title":"Blood"},{"issue":"9257","key":"10.1002\/14651858.CD002202.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(00)04132-5","article-title":"Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study","volume":"357","author":"Wierenga\u00a0KJ","year":"2001","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD002202.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/blood-2003-07-2475","article-title":"Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease","volume":"103","author":"Zimmerman","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD002202.pub2-BIB0199|cit199","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002202","article-title":"Hydroxyurea for sickle cell disease","author":"Jones","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd002202.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD002202.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T13:53:42Z","timestamp":1719150822000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD002202.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,4,20]]},"references-count":199,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002202.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,20]]}}}